Polycythemia vera (D45)
ICD-10 code D45 is used specifically to identify Polycythemia vera, a rare blood disorder characterized by an abnormal increase in red blood cells. This code helps healthcare providers accurately classify and document this condition for clinical care and reporting.
Polycythemia vera, also known as erythrocytosis due to polycythemia vera or polycythemia rubra vera, is a type of neoplasm that falls under “Neoplasms of unspecified nature.” This ICD-10 code covers various related conditions, including polycythemia vera in remission, myelofibrosis due to another disorder, and post-polycythemia vera myelofibrosis. Recognizing these synonyms is crucial for medical coders and clinicians dealing with billing and records. Using D45 ensures precise documentation of this complex blood disorder, which may involve complications like chorea, and allows for appropriate patient management and statistical tracking of the disease.
Instructional Notations
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Clinical Terms
The following clinical terms provide additional context, helping users better understand the clinical background and common associations for each diagnosis listed in this section. Including related terms alongside ICD-10-CM codes supports coders, billers, and healthcare professionals in improving accuracy, enhancing documentation, and facilitating research or patient education.
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
